Ian M. Catlett

Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain

James R. Burke, Lihong Cheng, Kathleen M. Gillooly et al. · Science Translational Medicine · 2019 · 282 citations

Life Sciences, Immunology, Pharmacology +14

Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase <scp>II</scp>, Randomized, <scp>Double‐Blind</scp>, <scp>Placebo‐Controlled</scp> Trial

Eric F. Morand, Marilyn C. Pike, Joan T. Merrill et al. · Arthritis & Rheumatology · 2022 · 248 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Immune Checkpoint Inhibition in Sepsis: A Phase 1b Randomized, Placebo-Controlled, Single Ascending Dose Study of Antiprogrammed Cell Death-Ligand 1 Antibody (BMS-936559)*

Richard S. Hotchkiss, Elizabeth Colston, Sachin Yende et al. · Critical Care Medicine · 2019 · 245 citations · Full text

Life Sciences, Immunology, Pharmacology +17

Recruitment of CD40 and Tumor Necrosis Factor Receptor-associated Factors 2 and 3 to Membrane Microdomains during CD40 Signaling

Bruce S. Hostager, Ian M. Catlett, Gail A. Bishop · Journal of Biological Chemistry · 2000 · 200 citations · Full text

Life Sciences, Cell Biology, Immunology +17

Immune checkpoint inhibition in sepsis: a Phase 1b randomized study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of nivolumab

Richard S. Hotchkiss, Elizabeth Colston, Sachin Yende et al. · Intensive Care Medicine · 2019 · 194 citations · Full text

Life Sciences, Pharmacokinetics, Pharmacology +12